GPR110在IA期肺腺癌不同亚型中表达差异及意义  

Expression and significance of GPR110 in different subtypes of stage IA lung adenocarcinoma

作　　者：张叶 余科科[2] 邢杰 丁闻洁 戎伟芳[1] Zhang Ye;Yu Keke;Xing Jie(Dept of Physiology,Basic Medical College,Shanghai Jiaotong University School of Medicine,Shanghai 200025;Dept of Biobank,Shanghai Chest Hospital,Shanghai Jiaotong University,Shanghai 200030)

机构地区：[1]上海交通大学医学院基础医学院生理学教研室,上海200025 [2]上海交通大学附属胸科医院(上海市胸科医院)生物样本库,上海200030 [3]上海交通大学附属胸科医院(上海市胸科医院)病理科,上海200030

出　　处：《安徽医科大学学报》2020年第7期1122-1125,共4页Acta Universitatis Medicinalis Anhui

基　　金：上海市卫生和计划生育委员会科研课题(编号:201740131);上海市胸科医院科技发展基金课题(编号:2018YNJCM01)。

摘　　要：目的探讨GPR110在Ia期肺腺癌不同病理组织亚型中的表达及其与临床病理特征、预后的关系。方法选取90例IA期肺腺癌病例;其中附壁生长组、腺泡/乳头组、微乳头/实体组各30例。采用免疫组织化学技术检测各组中GPR110蛋白表达情况。结果GPR110的表达与病理亚型具有相关性(P<0.05),与患者年龄、性别、肿块大小无相关性(P>0.05)。经COX回归分析,病理亚型对患者5年生存率产生影响,是影响预后的危险因素(P<0.05)。结论GPR110的高低表达与IA期肺腺癌病理亚型密切相关,GPR110可能是潜在的早期肺腺癌患者术后预防性治疗及危险性预测的新的靶分子。Objective To investigate the expression of GPR110 in different pathological subtypes of stage IA lung adenocarcinoma and its relationship with clinicopathological features and prognosis.Methods 90 cases of stage IA lung adenocarcinoma were selected.There were 30 cases each in the wall growth group,the acinar/nipple group and the micronipple/solid group.Immunohistochemistry was used to detect the expression of GPR110 protein in each group.Results The expression of GPR110 was correlated with the pathological subtype(P<0.05),but not with the patients’age,gender and tumor size(P>0.05).COX regression analysis showed that pathological subtype had an impact on the 5-year survival rate of patients.It was a risk factor for prognosis(P<0.05).Conclusion The high and low expression of GPR110 is closely related to the pathological subtype of stage IA lung adenocarcinoma,which may be a new biomarker for the potential prevention and risk prediction of early lung adenocarcinoma patients after surgery operation.

关 键 词：GPR110 肺腺癌 免疫组化 病理亚型 

分 类 号：R734.2[医药卫生—肿瘤]